(Q28292187)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807960

4 July 2024

3

Nilamadhab Kar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807960

4 July 2024

author name string

Vidhi Singh

2

0 references

Kelvin Chan

4

0 references

Surendra P. Singh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807960

full work available at URL

4 July 2024

language of work or name

English

0 references

publication date

September 2010

0 references

https://www.cambridge.org/core/services/aop-cambridge-core/content/view/2AB14664EA1ACC94C4F3879096853DF5/S0007125000015701a.pdf/div-class-title-efficacy-of-antidepressants-in-treating-the-negative-symptoms-of-chronic-schizophrenia-meta-analysis-div.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807960

http://intl-bjp.rcpsych.org/cgi/content/abstract/197/3/174

4 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807960

https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0007125000015701

4 July 2024

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

British Journal of Psychiatry

4 July 2024

published in

0 references

volume

197

0 references

issue

3

0 references

page(s)

174-9

0 references

cites work

Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia

1

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Negative symptoms in schizophrenia: a review

4 July 2024

2

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study

4 July 2024

3

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Amitriptyline versus other types of pharmacotherapy for depression

4 July 2024

4

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo

4 July 2024

5

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

A placebo-controlled clinical study with trazodone in schizophrenic patients

4 July 2024

6

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials.

4 July 2024

8

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Psychedelics and schizophrenia

4 July 2024

9

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Adjunctive trazodone in the treatment of negative symptoms of schizophrenia

4 July 2024

10

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia

4 July 2024

12

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

4 July 2024

13

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia

4 July 2024

14

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

4 July 2024

15

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

4 July 2024

16

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia

4 July 2024

17

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial

4 July 2024

18

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex

4 July 2024

20

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study

4 July 2024

21

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

4 July 2024

22

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms

4 July 2024

23

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia

4 July 2024

24

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia

4 July 2024

25

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

4 July 2024

27

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Fluoxetine augmentation of clozapine treatment in patients with schizophrenia

4 July 2024

28

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia

4 July 2024

29

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.

4 July 2024

30

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

4 July 2024

31

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study

4 July 2024

32

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

4 July 2024

33

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

4 July 2024

34

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials

4 July 2024

35

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

4 July 2024

36

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale

4 July 2024

37

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

4 July 2024

38

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial

4 July 2024

39

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial

4 July 2024

40

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

4 July 2024

41

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study

4 July 2024

43

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

4 July 2024

44

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710

Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study

4 July 2024

45

1 reference

https://api.crossref.org/works/10.1192/BJP.BP.109.067710